TNFRSF4 and atopic eczema: Clinical trials have demonstrated the significant reduction of symptoms in patients with atopic dermatitis treated with these antibodies, highlighting the effectiveness of OX40-targeting antibodies for the treatment of autoimmune diseases like AD.